The sale is minor relative to company size and likely routine; monitor for additional sales or participation from other insiders to assess potential concern.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 10 $74.32entry
- T+1 · 8mo ago −3.94%α −3.84% · $71.39
- T+5 · 8mo ago −4.55%α −3.64% · $70.94
- T+20 · 7mo ago −0.24%α −0.09% · $74.14
- T+60 · 6mo ago −11.89%α −23.30% · $65.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BridgeBio Pharma CEO Kumar Neil was granted a total of 144,883 shares in non-cash awards and sold 9,690 shares in an open-market transaction worth approximately $662,441. The sale represents a small fraction of the company's market cap and is likely part of a pre-arranged trading plan.
Key Financial Metrics
Key Facts
- CEO Kumar Neil received two non-cash stock awards totaling 144,883 shares with no economic value at grant.
- CEO sold 9,690 shares in an open-market transaction at $68.3634 per share, totaling $662,441.
- Total value of open-market sale is $662,441, representing approximately 0.0049% of BBIO's $13.6B market cap.
Financial Impact
$662,441 in open-market sales; no financial impact from non-cash grants
Risk Factors
- Non-cash grants may lead to future dilution, though standard for executive compensation.
- Single insider sale, even if small, could signal reduced conviction if followed by further selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (3 trades, 7d window) | cluster-BBIO-1773952120485 |
Track record
38 reports on BBIO
10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers